Who
Joana Goncalves
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Oruka Therapeutics; Chief Medical Officer, Tvardi Therapeutics.
In numbers
- Trades disclosed
- 198
- Buys
- 0
- Sells
- 38
- Bought
- $0
- Sold
- $10.3M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 22 Oct 2018
- Last trade
- 15 Oct 2026
- Last filed
- 15 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Oct 2026filed 15 Oct 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Code M | $24K3,500 at $6.84 | filing |
| 15 Oct 2026filed 15 Oct 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Code M | $27K3,500 at $7.80 | filing |
| 15 Oct 2026filed 15 Oct 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $211K2,853 at $73.89 | filing |
| 15 Oct 2026filed 15 Oct 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $138K1,847 at $74.69 | filing |
| 15 Oct 2026filed 15 Oct 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $106K1,400 at $75.48 | filing |
| 15 Oct 2026filed 15 Oct 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $54K700 at $76.67 | filing |
| 15 Oct 2026filed 15 Oct 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $16K200 at $77.71 | filing |
| 15 Oct 2026filed 15 Oct 2026 | ORKA Oruka Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,500 at $0.00 | filing |
| 15 Oct 2026filed 15 Oct 2026 | ORKA Oruka Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,500 at $0.00 | filing |
| 15 Sep 2026filed 15 Sep 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Code M | $24K3,500 at $6.84 | filing |
| 15 Sep 2026filed 15 Sep 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Code M | $27K3,500 at $7.80 | filing |
| 15 Sep 2026filed 15 Sep 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $217K2,384 at $91.10 | filing |
| 15 Sep 2026filed 15 Sep 2026 | ORKA Oruka Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,500 at $0.00 | filing |
| 15 Sep 2026filed 15 Sep 2026 | ORKA Oruka Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,500 at $0.00 | filing |
| 15 Sep 2026filed 15 Sep 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $290K3,150 at $92.03 | filing |
| 15 Sep 2026filed 15 Sep 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $127K1,366 at $92.99 | filing |
| 15 Sep 2026filed 15 Sep 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $9,422100 at $94.22 | filing |
| 15 Sep 2026filed 15 Sep 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $91K947 at $95.71 | filing |
| 15 Sep 2026filed 15 Sep 2026 | ORKA Oruka Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,500 at $0.00 | filing |
| 15 Sep 2026filed 15 Sep 2026 | ORKA Oruka Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,500 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.